# Thalidomide and Hydroxyurea Combination in β-Thalassemia Patients

> **NCT06153784** · PHASE2,PHASE3 · COMPLETED · sponsor: **Children's Hospital Karachi** · enrollment: 603 (actual)

## Conditions studied

- Thalassemia, Beta

## Interventions

- **DRUG:** Hydroxyurea and Thalidomide

## Key facts

- **NCT ID:** NCT06153784
- **Lead sponsor:** Children's Hospital Karachi
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-07
- **Primary completion:** 2023-07-30
- **Final completion:** 2023-07-30
- **Target enrollment:** 603 (ACTUAL)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06153784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06153784, "Thalidomide and Hydroxyurea Combination in β-Thalassemia Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06153784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*